相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biokinetics and Dosimetry of 177Lu-Pentixather
Heribert Haenscheid et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET
Andreas K. Buck et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT
Sebastian E. Serfling et al.
MOLECULAR IMAGING AND BIOLOGY (2022)
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
Liam Widjaja et al.
CANCERS (2021)
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Jan Styczynski et al.
BONE MARROW TRANSPLANTATION (2020)
The new biology of PTCL-NOS and AITL: current status and future clinical impact
Matthew A. Timmins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG
Qingqing Pan et al.
EJNMMI RESEARCH (2020)
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
Constantin Lapa et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation
Sabine Maurer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Stefan Habringer et al.
THERANOSTICS (2018)
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
Constantin Lapa et al.
THERANOSTICS (2017)
Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells
Darja Karpova et al.
BLOOD (2017)
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT
X. Cahu et al.
BONE MARROW TRANSPLANTATION (2016)
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen et al.
CLINICAL CANCER RESEARCH (2016)
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions
C. E. Hill-Kayser et al.
BONE MARROW TRANSPLANTATION (2011)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
F Reyes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1-Th2+immunophenotype
AP Weng et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
分享论文
